Healthcare is entering a new era, one defined by scientific innovation, cellular therapies, and a deeper understanding of human biology. As the field of regenerative medicine continues to evolve, companies at the forefront of discovery are helping redefine what may be possible for patients facing complex health challenges. Celularity is one such company, combining advanced research with a bold vision to expand the future of cellular medicine. At a time when healthcare systems around the world are searching for better ways to treat cancer, immune disorders, and other serious diseases, Celularity is looking to one of nature’s most powerful resources for answers. The company believes that the same biological mechanisms that help create and protect life may also hold the key to advancing the future of medicine.

This belief has shaped Celularity into a clinical-stage biotechnology company dedicated to developing innovative cellular therapies and regenerative solutions derived from the human placenta. While the science behind its work is highly sophisticated, the company’s purpose is deeply human: helping patients gain access to new treatment possibilities when they need them most.

The story of Celularity is not simply about biotechnology. It is about seeing value where others overlooked it. For decades, scientists understood that the placenta played a critical role in pregnancy, but its broader medical potential remained largely unexplored. Researchers began uncovering unique properties within placental cells, discovering characteristics that could support immune function, tissue repair, and regenerative processes. Celularity recognized an opportunity to turn those discoveries into real-world healthcare solutions.

What makes the company’s approach particularly compelling is its focus on accessibility. Many advanced cell therapies today are highly personalized, requiring complex manufacturing processes for individual patients. While these treatments can be groundbreaking, they are often difficult to scale. Celularity set out to address this challenge by developing therapies that can be produced in larger quantities and made available when needed.

Imagine a patient facing a serious illness. In many cases, time matters as much as treatment itself. The ability to provide therapies more efficiently can make a meaningful difference in a patient’s journey. Celularity’s platform is designed with this reality in mind, combining scientific innovation with a practical approach to healthcare delivery.

At the heart of the company’s work is a deep understanding of biology. The placenta performs one of nature’s most fascinating balancing acts. Throughout pregnancy, it protects and nurtures a developing baby while existing within the mother’s immune environment. Scientists have spent years studying this unique relationship, and Celularity has transformed those insights into a foundation for innovation.

Today, the company is advancing a broad portfolio of programs across oncology, immunology, and regenerative medicine. Its research includes Natural Killer cell therapies, engineered immune cells, and regenerative biomaterials designed to support healing and recovery. While each program targets a different medical challenge, they all share a common goal: helping the body do what it naturally does best, protect, heal, and restore itself. Beyond laboratories and clinical programs, Celularity’s work ultimately comes down to people. Behind every scientific milestone is a patient hoping for more time, a family searching for answers, or a healthcare professional looking for better treatment options. The company understands that innovation only matters when it creates meaningful impact in the lives of those it serves. This patient-centered mindset is reflected throughout the organization and is strongly influenced by its leadership. Founder, Chairman, and Chief Executive Officer Dr. Robert J. Hariri has spent much of his career exploring the intersection of science, medicine, and human potential. A physician, scientist, inventor, and entrepreneur, Dr. Hariri has long believed that some of healthcare’s most transformative breakthroughs can emerge from understanding the body’s own biological systems.

His vision helped establish the foundation of Celularity and continues to guide its direction today. Rather than focusing solely on scientific achievement, Dr. Hariri has championed the idea that innovation should ultimately improve lives. Under his leadership, Celularity has evolved into a company that combines scientific rigor with a genuine commitment to addressing unmet medical needs. Supporting this vision is a multidisciplinary team of researchers, clinicians, and biotechnology professionals who share a common purpose. Together, they are working to translate complex scientific discoveries into therapies that have the potential to change lives. Their efforts reflect a culture built on curiosity, collaboration, and a belief that medicine’s next great advances may come from understanding nature more deeply.

The healthcare industry is entering a new era, one where regenerative medicine and cellular therapies are becoming increasingly important. Yet progress in this field requires more than advanced technology. It requires imagination, perseverance, and the courage to challenge conventional thinking. Celularity has embraced all three.

Its journey demonstrates that innovation is not always about creating something entirely new. Sometimes it is about uncovering hidden potential in something that has been there all along. By transforming placental science into a platform for medical advancement, Celularity is helping redefine what cellular medicine can achieve. As the company continues to push the boundaries of biotechnology, its mission remains grounded in a simple but powerful truth: every scientific breakthrough is ultimately about people. It is about improving lives, creating possibilities, and offering hope where it is needed most.